Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4

Chloe Carmichael, Irina Jouravskaya, Elizabeth Collins, Danielle Burns, Jiat Ling Poon, Helen Kitchen, Donna Mojdami, Madhumita Murphy, Nadia Ahmad and Chisom Kanu ()
Additional contact information
Chloe Carmichael: Clarivate
Irina Jouravskaya: Eli Lilly and Company
Elizabeth Collins: Clarivate
Danielle Burns: Clarivate
Jiat Ling Poon: Eli Lilly and Company
Helen Kitchen: Clarivate
Donna Mojdami: Eli Lilly and Company
Madhumita Murphy: Eli Lilly and Company
Nadia Ahmad: Eli Lilly and Company
Chisom Kanu: Eli Lilly and Company

The Patient: Patient-Centered Outcomes Research, 2025, vol. 18, issue 3, No 4, 225-236

Abstract: Abstract Background and Objectives Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, which was approved in 2023 by the US Food and Drug Administration for weight management in adults with obesity or overweight. The purpose of this study was to conduct qualitative exit interviews with participants who had participated in the SURMOUNT-4 clinical trial, to better understand the patient experience of tirzepatide. Methods Online exit interviews were conducted with adults from the USA who had participated in the SURMOUNT-4 clinical trial for weight management, recruited from 16 US-based SURMOUNT-4 clinical sites. Interviews utilized a semi-structured interview guide, and included questions related to receiving tirzepatide, using a single-use injection pen device, and the overall trial experience. Interviews were audio recorded and transcribed, and analyzed using a content analysis. Results Eighty-six adults (83% female; mean age 49.9 years) participated in the interviews. All participants shared at least one perceived benefit of tirzepatide experienced during the open-label phase of SURMOUNT-4, including improved appetite control, increased energy, or improved clothing fit. Despite the gastrointestinal side effects experienced, many participants liked the efficacy of tirzepatide, and reported that the single-use injection pen device for administering the study medication was easy to use. Most participants were willing to continue taking tirzepatide. Conclusions Study findings showed that beyond the direct pharmacological effects of treatment with tirzepatide, participants reported a wide range of perceived improvements across several aspects of their lives. Participants also reported a few negative experiences, including side effects. It is possible that the participants who had a more positive experience were more inclined to participate in the exit interviews. This study highlights the value of exit interviews, which can provide more learning about patient experiences during a clinical trial.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-025-00730-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:18:y:2025:i:3:d:10.1007_s40271-025-00730-0

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-025-00730-0

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().